Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Prenatal Betamethasone interferes with immune system development and alters target cells in autoimmune diabetes.

Perna-Barrull D, Rodriguez-Fernandez S, Pujol-Autonell I, Gieras A, Ampudia-Carrasco RM, Villalba A, Glau L, Tolosa E, Vives-Pi M.

Sci Rep. 2019 Feb 4;9(1):1235. doi: 10.1038/s41598-018-37878-9.

2.

Autoreactive T effector memory differentiation mirrors β cell function in type 1 diabetes.

Yeo L, Woodwyk A, Sood S, Lorenc A, Eichmann M, Pujol-Autonell I, Melchiotti R, Skowera A, Fidanis E, Dolton GM, Tungatt K, Sewell AK, Heck S, Saxena A, Beam CA, Peakman M.

J Clin Invest. 2018 Aug 1;128(8):3460-3474. doi: 10.1172/JCI120555. Epub 2018 Jul 16.

3.

Phosphatidylserine-Liposomes Promote Tolerogenic Features on Dendritic Cells in Human Type 1 Diabetes by Apoptotic Mimicry.

Rodriguez-Fernandez S, Pujol-Autonell I, Brianso F, Perna-Barrull D, Cano-Sarabia M, Garcia-Jimeno S, Villalba A, Sanchez A, Aguilera E, Vazquez F, Verdaguer J, Maspoch D, Vives-Pi M.

Front Immunol. 2018 Feb 14;9:253. doi: 10.3389/fimmu.2018.00253. eCollection 2018.

4.

Expression of REG family genes in human inflammatory bowel diseases and its regulation.

Tsuchida C, Sakuramoto-Tsuchida S, Taked M, Itaya-Hironaka A, Yamauchi A, Misu M, Shobatake R, Uchiyama T, Makino M, Pujol-Autonell I, Vives-Pi M, Ohbayashi C, Takasawa S.

Biochem Biophys Rep. 2017 Oct 23;12:198-205. doi: 10.1016/j.bbrep.2017.10.003. eCollection 2017 Dec.

5.

Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes.

Alhadj Ali M, Liu YF, Arif S, Tatovic D, Shariff H, Gibson VB, Yusuf N, Baptista R, Eichmann M, Petrov N, Heck S, Yang JHM, Tree TIM, Pujol-Autonell I, Yeo L, Baumard LR, Stenson R, Howell A, Clark A, Boult Z, Powrie J, Adams L, Wong FS, Luzio S, Dunseath G, Green K, O'Keefe A, Bayly G, Thorogood N, Andrews R, Leech N, Joseph F, Nair S, Seal S, Cheung H, Beam C, Hills R, Peakman M, Dayan CM.

Sci Transl Med. 2017 Aug 9;9(402). pii: eaaf7779. doi: 10.1126/scitranslmed.aaf7779.

PMID:
28794283
6.

Liposome-based immunotherapy against autoimmune diseases: therapeutic effect on multiple sclerosis.

Pujol-Autonell I, Mansilla MJ, Rodriguez-Fernandez S, Cano-Sarabia M, Navarro-Barriuso J, Ampudia RM, Rius A, Garcia-Jimeno S, Perna-Barrull D, Martinez-Caceres E, Maspoch D, Vives-Pi M.

Nanomedicine (Lond). 2017 Jun;12(11):1231-1242. doi: 10.2217/nnm-2016-0410.

7.

Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis.

Stojanovic I, Dimitrijevic M, Vives-Pi M, Mansilla MJ, Pujol-Autonell I, Rodríguez-Fernandez S, Palova-Jelínkova L, Funda DP, Gruden-Movsesijan A, Sofronic-Milosavljevic L, Hilkens CMU, Martinez-Caceres E, Miljkovic D.

Curr Pharm Des. 2017;23(18):2623-2643. doi: 10.2174/1381612823666170214120708. Review.

PMID:
28201972
8.

Clinical-scale expansion of CD34+ cord blood cells amplifies committed progenitors and rapid scid repopulation cells.

Casamayor-Genescà A, Pla A, Oliver-Vila I, Pujals-Fonts N, Marín-Gallén S, Caminal M, Pujol-Autonell I, Carrascal J, Vives-Pi M, Garcia J, Vives J.

N Biotechnol. 2017 Mar 25;35:19-29. doi: 10.1016/j.nbt.2016.10.011. Epub 2016 Oct 31.

PMID:
27810336
9.

CD26/DPPIV inhibition alters the expression of immune response-related genes in the thymi of NOD mice.

Julián MT, Alonso N, Colobran R, Sánchez A, Miñarro A, Pujol-Autonell I, Carrascal J, Rodríguez-Fernández S, Ampudia RM, Vives-Pi M, Puig-Domingo M.

Mol Cell Endocrinol. 2016 May 5;426:101-12. doi: 10.1016/j.mce.2016.02.014. Epub 2016 Feb 18.

10.

B-cell anergy induces a Th17 shift in a novel B lymphocyte transgenic NOD mouse model, the 116C-NOD mouse.

Carrascal J, Carrillo J, Arpa B, Egia-Mendikute L, Rosell-Mases E, Pujol-Autonell I, Planas R, Mora C, Mauricio D, Ampudia RM, Vives-Pi M, Verdaguer J.

Eur J Immunol. 2016 Mar;46(3):593-608. doi: 10.1002/eji.201445376. Epub 2016 Jan 12.

11.

Type 1 Diabetes Prevention in NOD Mice by Targeting DPPIV/CD26 Is Associated with Changes in CD8⁺T Effector Memory Subset.

Alonso N, Julián MT, Carrascal J, Colobran R, Pujol-Autonell I, Rodriguez-Fernández S, Teniente A, Fernández MA, Miñarro A, Ruiz de Villa MC, Vives-Pi M, Puig-Domingo M.

PLoS One. 2015 Nov 10;10(11):e0142186. doi: 10.1371/journal.pone.0142186. eCollection 2015.

12.

What potential is there for liposomal-based nanotherapy for the treatment of Type 1 diabetes?

Vives-Pi M, Pujol-Autonell I.

Nanomedicine (Lond). 2015 Oct;10(19):2955-2958. doi: 10.2217/nnm.15.140. Epub 2015 Sep 30. No abstract available.

13.

Innovative immunological strategies for type 1 diabetes.

Vives-Pi M, Pujol-Autonell I.

Endocrinol Nutr. 2015 Nov;62(9):419-21. doi: 10.1016/j.endonu.2015.07.003. Epub 2015 Sep 3. English, Spanish. No abstract available.

PMID:
26342847
14.

Use of autoantigen-loaded phosphatidylserine-liposomes to arrest autoimmunity in type 1 diabetes.

Pujol-Autonell I, Serracant-Prat A, Cano-Sarabia M, Ampudia RM, Rodriguez-Fernandez S, Sanchez A, Izquierdo C, Stratmann T, Puig-Domingo M, Maspoch D, Verdaguer J, Vives-Pi M.

PLoS One. 2015 Jun 3;10(6):e0127057. doi: 10.1371/journal.pone.0127057. eCollection 2015.

15.

How apoptotic β-cells direct immune response to tolerance or to autoimmune diabetes: a review.

Vives-Pi M, Rodríguez-Fernández S, Pujol-Autonell I.

Apoptosis. 2015 Mar;20(3):263-72. doi: 10.1007/s10495-015-1090-8. Review.

16.

Efferocytosis promotes suppressive effects on dendritic cells through prostaglandin E2 production in the context of autoimmunity.

Pujol-Autonell I, Ampudia RM, Planas R, Marin-Gallen S, Carrascal J, Sanchez A, Marin A, Puig-Domingo M, Pujol-Borrell R, Verdaguer J, Vives-Pi M.

PLoS One. 2013 May 15;8(5):e63296. doi: 10.1371/journal.pone.0063296. Print 2013.

17.

Immunotherapy with Tolerogenic Dendritic Cells Alone or in Combination with Rapamycin Does Not Reverse Diabetes in NOD Mice.

Pujol-Autonell I, Ampudia RM, Monge P, Lucas AM, Carrascal J, Verdaguer J, Vives-Pi M.

ISRN Endocrinol. 2013;2013:346987. doi: 10.1155/2013/346987. Epub 2013 Mar 11.

18.

Biomarkers for diagnosis and monitoring of celiac disease.

Vives-Pi M, Takasawa S, Pujol-Autonell I, Planas R, Cabre E, Ojanguren I, Montraveta M, Santos AL, Ruiz-Ortiz E.

J Clin Gastroenterol. 2013 Apr;47(4):308-13. doi: 10.1097/MCG.0b013e31827874e3. Review.

PMID:
23388848
19.

Urinary levels of regenerating protein Iα do not differentiate celiac patients and healthy subjects.

Ruíz-Ortiz E, Santos AL, Pujol-Autonell I, Planas R, Montraveta M, Pintos G, Doladé M, Cabré E, Vives-Pi M.

Biomarkers. 2013 Mar;18(2):178-80. doi: 10.3109/1354750X.2012.745903. Epub 2013 Jan 11.

PMID:
23312007
20.

Regenerating gene Iα is a biomarker for diagnosis and monitoring of celiac disease: a preliminary study.

Planas R, Pujol-Autonell I, Ruiz E, Montraveta M, Cabre E, Lucas-Martin A, Pujol-Borrell R, Martinez-Caceres E, Vives-Pi M.

Transl Res. 2011 Sep;158(3):140-5. doi: 10.1016/j.trsl.2011.04.004. Epub 2011 May 30.

PMID:
21867979
21.

CCL4L polymorphisms and CCL4/CCL4L serum levels are associated with psoriasis severity.

Pedrosa E, Carretero-Iglesia L, Boada A, Colobran R, Faner R, Pujol-Autonell I, Palou E, Esteve A, Pujol-Borrell R, Ferrándiz C, Juan M, Carrascosa JM.

J Invest Dermatol. 2011 Sep;131(9):1830-7. doi: 10.1038/jid.2011.127. Epub 2011 May 26.

22.

Dendritic cells pulsed with antigen-specific apoptotic bodies prevent experimental type 1 diabetes.

Marin-Gallen S, Clemente-Casares X, Planas R, Pujol-Autonell I, Carrascal J, Carrillo J, Ampudia R, Verdaguer J, Pujol-Borrell R, Borràs FE, Vives-Pi M.

Clin Exp Immunol. 2010 May;160(2):207-14. doi: 10.1111/j.1365-2249.2009.04082.x. Epub 2009 Dec 17.

Supplemental Content

Loading ...
Support Center